Royalty Pharma RPRX Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total income and other revenues by Product | ||||||
| Income from financial royalty assets | $2.32B+2.5% | $2.26B+1.4% | $2.23B+2.1% | $2.18B+1.7% | $2.15B-0.1% | |
| Other royalty income and revenues | $123.87M+5.8% | $117.04M-1.9% | $119.28M-0.9% | $120.32M+3.3% | $116.48M+2.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Royalty Pharma break its business down?
- Royalty Pharma (RPRX) reports total income and other revenues by product across 2 parts — Income from financial royalty assets and Other royalty income and revenues. Each is extracted from the segment footnotes and tracked over time.
- Where does Royalty Pharma's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Royalty Pharma's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
